News
INVO Bioscience Reports 2020 Financial Results
Company to Host Conference Call on March 30 at 4:30pm ET (Details Below)SARASOTA, Fla., March 30, 2021 -- INVO Bioscience, Inc. (Nasdaq: INVO), a medical device company focused on creating alternative treatments for patients diagnosed with infertility and developers...
INVO Bioscience to Present at the Lytham Partners Spring 2021 Investor Conference
SARASOTA, Fla., March 29, 2021 -- INVO Bioscience, Inc. (NASDAQ: INVO), a medical device company focused on commercializing the world's only in vivo Intravaginal Culture System (IVC), INVOcell®, an effective and affordable treatment for patients diagnosed with...
INVO Bioscience to Report Fourth Quarter and Fiscal Year 2020 Financial Results on Tuesday, March 30, 2021
Financial results to be released after market close; Conference call to be conducted at 4:30 pm ETSARASOTA, Fla., March 26, 2021 -- INVO Bioscience, Inc. (NASDAQ: INVO), a medical device company focused on commercializing the world's only in vivo Intravaginal Culture...
INVO Bioscience Achieves Key Milestone – Signs Agreement to Open First Joint Venture INVOcell Clinic in the United States
INVO has partnered with experienced reproductive specialists who are strong advocates of the INVOcell solutionClinic to be located in Birmingham, Alabama with a focus on providing INVOcell as an efficient, effective and affordable fertility treatment option for the...
INVO Bioscience to Participate in the 33rd Annual Roth Conference
SARASOTA, Fla., March 11, 2021 -- INVO Bioscience, Inc. (NASDAQ: INVO), a medical device company focused on commercializing the world's only in vivo Intravaginal Culture System (IVC), INVOcell®, an effective and affordable treatment for patients diagnosed with...
INVO Bioscience Expands Company-Owned Clinic Opportunity Under Amended U.S. Commercialization Agreement
SARASOTA, Fla., March 8, 2021 -- INVO Bioscience, Inc. (NASDAQ: INVO), a medical device company focused on commercializing the world's only in vivo Intravaginal Culture System (IVC), INVOcell®, an effective and affordable treatment for patients diagnosed with...
INVO Bioscience Obtains Regulatory Approval to Import INVOcell Into Mexico
SARASOTA, Fla., March 1, 2021 -- INVO Bioscience, Inc. (NASDAQ: INVO), a medical device company focused on commercializing the world's only in vivo Intravaginal Culture System (IVC), INVOcell®, an effective and affordable treatment for patients diagnosed with...
INVO Bioscience Advances Commercialization into the European Fertility Market with Initial Orders of INVOcell (IVC) in Spain
- Spain marks INVO's initial entry into the European market- Europe represents approximately 30% of the multi-billion dollar global fertility marketplace- The first three clinics in Spain have placed initial orders for INVOcell - an effective and affordable...
INVO Bioscience Expands Distribution of INVOcell Into the Pakistan Infertility Market with Galaxy Pharma Ltd.
- Signs distribution agreement with Galaxy Pharma Ltd., the clear market leader of infertility products and services in Pakistan- Seeks to expand access to infertility care in the fifth most populous country in the world, Pakistan, with approximately 212 million...
INVO Bioscience Management Letter to Shareholders
Key Developments and Future Initiatives Position INVOcell® Within the Severely Underserved Fertility MarketSARASOTA, Fla., Jan. 7, 2021 -- INVO Bioscience, Inc. (NASDAQ: INVO) ("Company") ('INVO"), a medical device company focused on commercializing the world's...